Intervention to Increase Chemotherapy Tolerance in Elderly Cancer Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Colonic Neoplasms
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Participant satisfaction with intervention structure, timing and content
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to develop and pilot test a behavioral intervention for elderly adults in treatment for colon cancer, to enhance their skills for managing the challenges of completing chemotherapy regimens. The investigators will assess feasibility and acceptability of the intervention, and explore preliminary efficacy of the intervention for reducing psychological distress and improving rates of optimal chemotherapy adherence.
Investigators
Lara Traeger
Assistant in Psychology
Massachusetts General Hospital
Eligibility Criteria
Inclusion Criteria
- •Age 60 or older
- •Verbal fluency in English
- •Diagnosis of colon cancer
- •Scheduled to initiate chemotherapy treatment for colon cancer
Exclusion Criteria
- •Active, unstable, untreated serious mental illness interfering with ability to participate
- •Cognitive impairment interfering with ability to participate
- •Receiving radiotherapy concomitant with chemotherapy
Outcomes
Primary Outcomes
Participant satisfaction with intervention structure, timing and content
Time Frame: At approximately 12 weeks post-baseline
Participants rate acceptability of structure, timing and content of intervention using Likert-type response scales, and are also invited to provide brief qualitative feedback on opinions about intervention.
Number of participants who withdraw from study after enrollment
Time Frame: At approximately 12 weeks post-baseline
Secondary Outcomes
- Change from baseline in the Hospital Anxiety and Depression Scale(At approximately 12 weeks post-baseline)
- Change from baseline in the Symptom Distress Scale(At approximately 12 weeks post-baseline)
- Proportion of each chemotherapy component administered during the treatment regimen relative to the total planned amount(At approximately 24 weeks post-baseline)